The MIT School of Engineering has launched the Hood Pediatric Innovation Hub to address “underinvestment in pediatric healthcare innovations,” reports Isabel Hart for Boston Business Journal. “We are trying to build a new culture providing innovation to those who have least access to it and will most benefit from it,” says Prof. Elazer Edelman, the faculty lead at the hub.
Syntis Bio, a biopharmaceutical company co-founded by Prof. Giovanni Traverso and Prof. Robert Langer, is developing a daily obesity pill that mimics the effects of gastric bypass, reports Emily Mullin for Wired. “This material is something you would take as a capsule or liquid, but the next day it's gone because of the natural turnover of our mucosal surface in the GI tract,” says Traverso.
“AT MIT innovation ranges from awe-inspiring technology to down-to-earth creativity,” notes Chronicle during a visit to campus to peek behind the scenes at the innovations underway at the Institute. Classes taught by Prof. Erik Demaine are a “mix of rigorous math and creative collaboration,” host Anthony Everett explains, highlighting how Demaine’s work in computational origami has found its way into practical applications in such fields as medicine, architecture and space exploration. “I think origami provides a really powerful tool for making transformable shapes,” Demaine relates.
Chronicle visits MIT to learn more about how the Institute “nurtures groundbreaking efforts, reminding us that creativity and science thrive together, inspiring future advancements in engineering, medicine, and beyond.” Prof. Julien de Wit and Research Scientist Artem Burdanov discuss their planetary defense efforts aimed at identifying small asteroids that could pose a threat to Earth, and Prof. Canan Dağdeviren demonstrates her work developing ultrasound devices to detect the earliest stages of breast cancer. Host Anthony Everett notes that: “Big ideas have a way of breaking out of conventional boundaries, just part of what makes MIT one giant laboratory of groundbreaking ideas."
MIT researchers have developed “self-injectable contraceptive shots that work similarly to contraceptive implants,” reports Margherita Bassi for Gizmodo. “The shots would result in a highly effective and long-term contraceptive method more accessible to women who lack easy access to medical infrastructure,” explains Bassi. “Additionally, the design could be used to administer other long-term medications, such as those for HIV.”
MIT researchers have developed a “simple way to administer long-acting drug delivery systems without the need for invasive procedures – an appealing prospect for parts of the world with poor medical infrastructure,” reports Nicola Davis for The Guardian. “It’s suitable for any poorly soluble hydrophobic drug, especially where long-acting delivery is needed,” says Prof. Giovanni Traverso, “This includes treatments for HIV, TB, schizophrenia, chronic pain, or metabolic disease.”
Prof. Jeffrey Harris speaks with Newsweek reporter Jasmine Laws about how a recession could impact Medicare. "A recession could impact many critical decisions of federal lawmakers, private insurers, healthcare providers, and patients,” says Harris. “The U.S. Congress may decide to let stand the Medicare physician payment cut that became effective on January 1 of this year. Reduced physician payments under conventional Medicare may cause doctors, hospitals and other providers to shift their resources toward the care of younger, commercially insured patients."
Researchers from MIT have “identified genes that the tuberculous bacteria rely on to survive and spread,” reports Allison DeAngelis for STAT. “Until now, very little was known about how tuberculous bacteria survived temperature changes, oxygen levels, humidity, and other environmental factors during the journey from one person’s lungs to another’s,” explains DeAngelis.
Writing for The Boston Globe, Prof. Pierre Azoulay and Prof. Jeffrey Flier of Harvard Medical School make the case that any reforms at the NIH “should be grounded in evidence rather than tradition, avoiding the influence of special interests or political considerations.” They add that this approach “is an acknowledgement of NIH’s accomplishments and a charge to adapt it to the new realities of 21st-century science. The overarching goal must be to secure and enhance the decades-long role of the United States at the forefront of biomedical research, an outcome that the public both wants and deserves.”
MIT has multiple projects represented in this year’s STAT Madness, a bracket-style competition “highlighting important scientific advances emerging from labs at the nation’s universities, medical schools, and other U.S. research institutions and companies,” reports STAT staff.
MIT researchers have developed a technique to use a damage suppressing protein called “Dsup” to help protect cancer patients from the side effects of radiation therapy, writes Shane Galvin for The New York Post. “Scientists, encouraged by this remarkable discovery, believe they can create an upgraded version of Dsup which can be used to radiation-proof human cells without any unwanted drawbacks,” writes Galvin. “They also believe that the protein could be used by astronauts to prevent space-related radiation [damage].”
Researchers at MIT and elsewhere have found that a protein developed by tardigrades could be used to help protect cancer patients from the side effects of radiation therapy, reports Ed Cara for Gizmodo. “The findings could someday lead to an invaluable add-on treatment for many cancer patients,” writes Cara. He adds that the new technique “could even possibly be used to protect astronauts from space-related radiation or to protect cancer patients from other sources of treatment-induced DNA damage, such as chemotherapy drugs.”
According to a new study co-authored by researchers at MIT, harnessing the damage suppressor protein found in tardigrades, a microscopic organism known for its resilience, could help ease the impacts of radiation therapy on cancer patients. “The Dsup protein, which binds directly to DNA and reduces radiation-induced strand breaks, immediately struck us as a promising tool to mitigate normal tissue injury during radiotherapy,” Prof. Giovanni Traverso explains to Corinna Singleman of Genetic Engineering & Biotechnology News.
Writing for Forbes, Paula Schneider, CEO of Susan G. Komen, highlights Prof. Regina Barzilay’s research using AI to detect breast cancer. “Using her own mammograms in her research at MIT, Dr. Barzilay demonstrated how AI could have detected her breast cancer much earlier, potentially improving her prognosis,” writes Schneider. “Studies show that incorporating AI into mammogram analysis boosts cancer detection rates by 20%, without increasing false positives. This is a significant leap forward, as early detection is key to a better chance at positive outcomes and survival.”
Evan Ehrenberg PhD '16 co-founded Waterlily, a company that “uses artificial intelligence to predict a family’s future long-term care needs and costs” with the right care and financial planning, reports Mary Ann Azevedo for TechCrunch. “Ehrenberg — who had previously founded and sold Clara Health — helped with early research and was struck by the industry’s response,” writes Azevedo. “Curious, he tested the platform and was shocked by his long-term care predictions — so much so that he changed his diet, hired a personal trainer, and updated his financial plans.”